Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregon, M, Campos, B, Coves, J, De Castro, J, Domènech, M, Domine, M, Campelo, RG, Gozálvez, CL, Huidobro, G, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares, A, Reguart, N, Sala, MA, Medina, K, Vilà, L, Massuti, B. ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Sanchez, AYC, Bustillos, A, Herraez-Baranda, L, Barata, T, Young, F, Majem, M. IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Grohé, C, Wu, YL, Tsuboi, M, Majem, M, John, T, Bolanos, A, Taylor, R, Sandelin, M, Herbst, RS. Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Wang, M, Jänne, PA, Doucet, L, Fan, Y, Lv, D, Sun, M, Huang, D, Greillier, L, Planchard, D, Hong, Q, Mazieres, J, Felip, E, Li, X, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Ferreira, BP, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, R, Zalcman, G, Carpeño, JD, Di Noia, V, Parra, HS, Streich, G, Lee, D, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquín, AB, Liu, G, Antonuzzo, L, Fernandez-Hinojal, G, Le, X, Zheng, L, Yang, JCH. A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).

Audisio, A, Gallio, C, Velenik, V, Meillat, H, Ruiz-Garcia, E, Riesco, MC, Alecha, JS, Rasschaert, G, Carvalho, C, Randrian, V, Kirac, I, Hernando, J, Artac, M, O'Connor, JM, Waldhorn, I, Braam, PM, Shamseddine, A, Moretto, R, de la Pinta, C, De Felice, F, Dulskas, A, Lopez-Bravo, DP, Vanden Bulcke, A, Bock, F, Deleporte, A, van den Eynde, M, Geboes, KP, Loi, M, Messina, M, Houlze-Laroye, C, Puccini, A, Pastorino, A, Papamichael, D, Fiore, M, Sur, D, Eid, M, Antoun, C, Salati, M, Garajova, I, Jakubauskas, M, Tomasek, J, Pinto, CMS, Schwingel, J, Morano, F, Adams, RA, Dermine, A, Chau, A, Javed, MA, Ghidini, M, Fiorica, F, Montenegro, P, Petrillo, A, Spolverato, G, Margalef, NM, Diaz, M, Baratelli, C, Puleo, F, Karampeazis, A, Sert, F, Gilliaux, Q, De Stefano, A, Liberale, G, Moretti, L, Martinive, P, Thomas, VD, Staggs, V, Saad, ED, Van Laethem, JL, Sclafani, F. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology. 2025; 11(9)DOI:10.1001/jamaoncol.2025.2026. PMID:40638097. IF:20.100(Q1/1D).

Alamo, P, López-Laguna, H, Favaro, MTP, Gallardo, A, Alba-Castellon, L, Villaverde, A, Mangues, R, Vázquez, E. Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein. INTERNATIONAL JOURNAL OF PHARMACEUTICS. 2026; 690DOI:10.1016/j.ijpharm.2026.126585. PMID:41521013. IF:5.200(Q1/2D).

Sanchez, JM, Voltà-Durán, E, Parladé, E, Mangues, R, Villaverde, A, Vázquez, E, Unzueta, U. Surpassing protein specificity in biomimetics of bacterial amyloids. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2025; 296DOI:10.1016/j.ijbiomac.2025.139635. PMID:39788253. IF:8.500(Q1/1D).